Clinical date
A total of 474 patients with colorectal cancer attending the Department
of Oncology of the Second Affiliated Hospital of Air Force Military
Medical University from October 2019 to February 2023 were initially
included in this study, and those with one of the following conditions
were excluded by the exclusion criteria: (1) patients without a
definitive pathological diagnosis; (2) patients receiving postoperative
adjuvant chemotherapy or regular follow-up; (3) patients without target
lesions who cannot be evaluated for RESIST 1.1; (4) patients with
advanced colorectal cancer receiving first-line treatment at first
diagnosis; (5) patients with a combination of 2 or more malignancies;
(6) end-stage patients receiving palliative symptomatic supportive care;
(7) patients with unsuccessful follow-up or incomplete case data.
Finally, 127 patients were included, 87 males; 40 females; the age range
was 41-81 years old, with a median age of 60 years; there were 65
patients who received immune checkpoint inhibitors(ICI) and 62 patients
who did not receive immune checkpoint inhibitors; 84 cases of left colon
cancer (including left transverse colon, descending colon, and sigmoid
colon), and 43 cases of right colon cancer (including cecum, ascending
colon, and right transverse colon); 9 cases of patients with dMMR, and
118 cases of patients with pMMR; 63 cases of patients with KRAS mutant
type, and 64 cases of patients with KRAS wild type; 86 cases of patients
who combined targeted therapy in the course of treatment, 41 cases of
patients who did not combine targeted therapy, specific detailed data
are shown in Table 1.
Table 1 Patient Characteristics